Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
haemophilus influenzae type b vaccine (tetanus toxoid conjugated)
- Development stage
- Approved
- Lead developer
- Sanofi
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**Haemophilus influenzae type b vaccine (tetanus toxoid conjugated)** is an inactivated, conjugate vaccine for intramuscular use, designed to prevent invasive disease caused by Haemophilus influenzae type b (Hib), including meningitis, bacteremia, and pneumonia. The vaccine contains a purified polysaccharide (polyribosyl-ribitol-phosphate, PRP) derived from the Hib capsular antigen, covalently bound to tetanus toxoid, which serves as a carrier protein to significantly enhance immune response in infants and young children. It induces the production of anti-PRP antibodies that confer protection against Hib invasive disease. This vaccine is not a substitute for regular tetanus immunization. Approved for use as primary and booster immunization in children 6 weeks to 4 years of age[1][2][5][6].
- Brand names
- ActHIBHiberixPedvaxHIBPentacel
- Other names
- haemophilus b conjugate vaccine (tetanus toxoid conjugate)haemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigenhaemophilus influenzae type b strain 20752 capsular polysaccharide tetanus toxoid conjugate antigenhib vaccine (tetanus toxoid conjugated)PRP-Thaemophilus b-PRP and tetanus toxoid conjugate (PRP-T)
02
Targets
TT (Tetanus toxoid)
Beyond the preview
Go deeper on haemophilus influenzae type b vaccine (tetanus toxoid conjugated).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on haemophilus influenzae type b vaccine (tetanus toxoid conjugated).